0001337013falseDecember 31Q32021P1Y00013370132021-01-012021-09-30xbrli:shares00013370132021-11-10iso4217:USD00013370132021-09-3000013370132020-12-31iso4217:USDxbrli:shares00013370132021-07-012021-09-3000013370132020-07-012020-09-3000013370132020-01-012020-09-300001337013us-gaap:CommonStockMember2020-06-300001337013us-gaap:AdditionalPaidInCapitalMember2020-06-300001337013us-gaap:RetainedEarningsMember2020-06-300001337013us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300001337013us-gaap:TreasuryStockMember2020-06-3000013370132020-06-300001337013us-gaap:CommonStockMember2020-07-012020-09-300001337013us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300001337013us-gaap:RetainedEarningsMember2020-07-012020-09-300001337013us-gaap:CommonStockMember2020-09-300001337013us-gaap:AdditionalPaidInCapitalMember2020-09-300001337013us-gaap:RetainedEarningsMember2020-09-300001337013us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-300001337013us-gaap:TreasuryStockMember2020-09-3000013370132020-09-300001337013us-gaap:CommonStockMember2021-06-300001337013us-gaap:AdditionalPaidInCapitalMember2021-06-300001337013us-gaap:RetainedEarningsMember2021-06-300001337013us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001337013us-gaap:TreasuryStockMember2021-06-3000013370132021-06-300001337013us-gaap:CommonStockMember2021-07-012021-09-300001337013us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001337013us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300001337013us-gaap:RetainedEarningsMember2021-07-012021-09-300001337013us-gaap:CommonStockMember2021-09-300001337013us-gaap:AdditionalPaidInCapitalMember2021-09-300001337013us-gaap:RetainedEarningsMember2021-09-300001337013us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300001337013us-gaap:TreasuryStockMember2021-09-300001337013us-gaap:CommonStockMember2019-12-310001337013us-gaap:AdditionalPaidInCapitalMember2019-12-310001337013us-gaap:RetainedEarningsMember2019-12-310001337013us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001337013us-gaap:TreasuryStockMember2019-12-3100013370132019-12-310001337013us-gaap:CommonStockMember2020-01-012020-09-300001337013us-gaap:AdditionalPaidInCapitalMember2020-01-012020-09-300001337013us-gaap:RetainedEarningsMember2020-01-012020-09-300001337013us-gaap:CommonStockMember2020-12-310001337013us-gaap:AdditionalPaidInCapitalMember2020-12-310001337013us-gaap:RetainedEarningsMember2020-12-310001337013us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001337013us-gaap:TreasuryStockMember2020-12-310001337013us-gaap:CommonStockMember2021-01-012021-09-300001337013us-gaap:AdditionalPaidInCapitalMember2021-01-012021-09-300001337013us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-09-300001337013us-gaap:RetainedEarningsMember2021-01-012021-09-300001337013infu:FilAMedMember2021-01-012021-09-300001337013infu:OBHealthcareMember2021-01-012021-09-300001337013infu:FilAMedMember2021-01-310001337013infu:OBHealthcareMember2021-04-180001337013infu:OBHealthcareMember2021-04-182021-04-180001337013infu:OBHealthcareMember2021-07-012021-09-300001337013infu:OBHealthcareMemberus-gaap:OtherCurrentLiabilitiesMember2021-04-180001337013infu:OBHealthcareMember2021-09-300001337013us-gaap:CustomerRelationshipsMember2021-09-300001337013us-gaap:CustomerRelationshipsMember2021-01-012021-09-300001337013us-gaap:TechnologyBasedIntangibleAssetsMember2021-09-300001337013us-gaap:TechnologyBasedIntangibleAssetsMember2021-01-012021-09-300001337013us-gaap:NoncompeteAgreementsMember2021-09-300001337013us-gaap:NoncompeteAgreementsMember2021-01-012021-09-300001337013us-gaap:ComputerSoftwareIntangibleAssetMember2021-09-300001337013us-gaap:ComputerSoftwareIntangibleAssetMember2021-01-012021-09-300001337013us-gaap:GeneralAndAdministrativeExpenseMember2021-07-012021-09-300001337013us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-09-300001337013infu:ThirdPartyPayerRentalRevenueMember2021-07-012021-09-30xbrli:pure0001337013infu:ThirdPartyPayerRentalRevenueMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-07-012021-09-300001337013infu:ThirdPartyPayerRentalRevenueMember2020-07-012020-09-300001337013infu:ThirdPartyPayerRentalRevenueMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-07-012020-09-300001337013infu:DirectPayerRentalsMember2021-07-012021-09-300001337013us-gaap:CustomerConcentrationRiskMemberinfu:DirectPayerRentalsMemberus-gaap:SalesRevenueNetMember2021-07-012021-09-300001337013infu:DirectPayerRentalsMember2020-07-012020-09-300001337013us-gaap:CustomerConcentrationRiskMemberinfu:DirectPayerRentalsMemberus-gaap:SalesRevenueNetMember2020-07-012020-09-300001337013infu:ProductSalesMember2021-07-012021-09-300001337013us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberinfu:ProductSalesMember2021-07-012021-09-300001337013infu:ProductSalesMember2020-07-012020-09-300001337013us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberinfu:ProductSalesMember2020-07-012020-09-300001337013us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-07-012021-09-300001337013us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-07-012020-09-300001337013infu:ThirdPartyPayerRentalRevenueMember2021-01-012021-09-300001337013infu:ThirdPartyPayerRentalRevenueMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-01-012021-09-300001337013infu:ThirdPartyPayerRentalRevenueMember2020-01-012020-09-300001337013infu:ThirdPartyPayerRentalRevenueMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-01-012020-09-300001337013infu:DirectPayerRentalsMember2021-01-012021-09-300001337013us-gaap:CustomerConcentrationRiskMemberinfu:DirectPayerRentalsMemberus-gaap:SalesRevenueNetMember2021-01-012021-09-300001337013infu:DirectPayerRentalsMember2020-01-012020-09-300001337013us-gaap:CustomerConcentrationRiskMemberinfu:DirectPayerRentalsMemberus-gaap:SalesRevenueNetMember2020-01-012020-09-300001337013infu:ProductSalesMember2021-01-012021-09-300001337013us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberinfu:ProductSalesMember2021-01-012021-09-300001337013infu:ProductSalesMember2020-01-012020-09-300001337013us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberinfu:ProductSalesMember2020-01-012020-09-300001337013us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-01-012021-09-300001337013us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-01-012020-09-300001337013infu:DirectPayerRentalsMemberinfu:ITSSegmentMember2021-07-012021-09-300001337013infu:DirectPayerRentalsMemberinfu:DMEServicesSegmentMember2021-07-012021-09-300001337013infu:DirectPayerRentalsMemberinfu:ITSSegmentMember2020-07-012020-09-300001337013infu:DirectPayerRentalsMemberinfu:DMEServicesSegmentMember2020-07-012020-09-300001337013infu:DirectPayerRentalsMemberinfu:ITSSegmentMember2021-01-012021-09-300001337013infu:DirectPayerRentalsMemberinfu:DMEServicesSegmentMember2021-01-012021-09-300001337013infu:DirectPayerRentalsMemberinfu:ITSSegmentMember2020-01-012020-09-300001337013infu:DirectPayerRentalsMemberinfu:DMEServicesSegmentMember2020-01-012020-09-300001337013us-gaap:FurnitureAndFixturesMember2021-09-300001337013us-gaap:FurnitureAndFixturesMember2020-12-310001337013us-gaap:AutomobilesMember2021-09-300001337013us-gaap:AutomobilesMember2020-12-310001337013us-gaap:LeaseholdImprovementsMember2021-09-300001337013us-gaap:LeaseholdImprovementsMember2020-12-310001337013infu:DMEServicesSegmentMember2020-12-310001337013infu:DMEServicesSegmentMember2021-01-012021-09-300001337013infu:DMEServicesSegmentMember2021-09-300001337013us-gaap:TradeNamesMember2021-09-300001337013us-gaap:TradeNamesMember2020-12-310001337013infu:PhysicianAndCustomerRelationshipsMember2021-09-300001337013infu:PhysicianAndCustomerRelationshipsMember2020-12-310001337013us-gaap:NoncompeteAgreementsMember2020-12-310001337013us-gaap:TechnologyBasedIntangibleAssetsMember2020-12-310001337013us-gaap:ComputerSoftwareIntangibleAssetMember2020-12-310001337013infu:The2021CreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2021-02-050001337013infu:The2021CreditAgreementMemberus-gaap:LetterOfCreditMember2021-02-050001337013infu:The2021CreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2021-02-052021-02-050001337013infu:The2015CreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2021-02-052021-02-050001337013infu:The2021CreditAgreementMember2021-02-052021-02-050001337013infu:The2021CreditAgreementMember2021-02-050001337013infu:The2015CreditAgreementMember2021-02-050001337013infu:ThreeTermNotesAssociatedWithThe2015CreditAgreementMember2020-12-310001337013us-gaap:RevolvingCreditFacilityMemberinfu:CreditFacilityMember2020-12-310001337013infu:EurodollarLoanMemberinfu:CreditFacilityMembersrt:MinimumMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-01-012020-12-310001337013infu:EurodollarLoanMembersrt:MaximumMemberinfu:CreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-01-012020-12-310001337013infu:CBFloatingRateLoanMemberinfu:CreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-01-012020-12-310001337013infu:CBFloatingRateLoanMemberinfu:CreditFacilityMemberinfu:GreaterOfPrimeRateOrLIBORPlus25Membersrt:MinimumMember2020-01-012020-12-310001337013infu:CBFloatingRateLoanMembersrt:MaximumMemberinfu:CreditFacilityMemberinfu:GreaterOfPrimeRateOrLIBORPlus25Member2020-01-012020-12-310001337013infu:EurodollarLoanMemberinfu:CreditFacilityMember2020-12-310001337013infu:EurodollarLoanMemberinfu:CreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-01-012020-12-310001337013infu:CBFloatingRateLoanMemberinfu:CreditFacilityMember2020-12-310001337013infu:CBFloatingRateLoanMemberinfu:CreditFacilityMemberinfu:CBFloatingRateMember2020-12-310001337013infu:CBFloatingRateLoanMemberinfu:CreditFacilityMemberinfu:CBFloatingRateMember2020-01-012020-12-310001337013infu:MedicalEquipmentMemberinfu:FinancingAgreementMember2019-04-150001337013infu:MedicalEquipmentMemberinfu:FinancingAgreementMember2019-04-152019-04-150001337013infu:MedicalEquipmentMemberinfu:FinancingAgreementMember2021-09-300001337013us-gaap:RevolvingCreditFacilityMember2021-09-300001337013us-gaap:RevolvingCreditFacilityMember2020-12-310001337013infu:FinancingAgreementMember2021-09-300001337013infu:TermLoanMember2021-09-300001337013infu:TermLoanMember2020-12-310001337013infu:EquipmentLineMember2021-09-300001337013infu:EquipmentLineMember2020-12-310001337013infu:The2019EquipmentLineMember2021-09-300001337013infu:The2019EquipmentLineMember2020-12-310001337013infu:FinancingAgreementMember2020-12-310001337013infu:EurodollarLoanMemberinfu:The2021CreditAgreementMembersrt:MinimumMemberus-gaap:LondonInterbankOfferedRateLIBORMember2021-01-012021-09-300001337013infu:EurodollarLoanMemberinfu:The2021CreditAgreementMembersrt:MaximumMemberus-gaap:LondonInterbankOfferedRateLIBORMember2021-01-012021-09-300001337013infu:The2021CreditAgreementMemberus-gaap:BaseRateMemberinfu:ABRLoansMembersrt:MinimumMember2021-01-012021-09-300001337013infu:The2021CreditAgreementMembersrt:MaximumMemberus-gaap:BaseRateMemberinfu:ABRLoansMember2021-01-012021-09-300001337013infu:EurodollarLoanMemberinfu:The2021CreditAgreementMember2021-09-300001337013infu:EurodollarLoanMemberinfu:The2021CreditAgreementMemberus-gaap:LondonInterbankOfferedRateLIBORMember2021-01-012021-09-300001337013infu:The2021CreditAgreementMemberinfu:ABRLoansMember2021-09-300001337013infu:The2021CreditAgreementMemberus-gaap:BaseRateMemberinfu:ABRLoansMember2021-01-012021-09-30infu:agreements0001337013us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2021-02-050001337013us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2021-02-052021-02-050001337013us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:OtherNoncurrentAssetsMember2021-09-300001337013us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-06-300001337013us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-12-310001337013us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-07-012021-09-300001337013us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-01-012021-09-300001337013us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-09-300001337013us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2021-01-012021-09-300001337013us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2021-07-012021-09-300001337013srt:MaximumMember2020-01-012020-09-300001337013srt:MaximumMember2020-07-012020-09-300001337013us-gaap:OtherLiabilitiesMember2021-09-300001337013infu:OfficeLeasesWithRenewalOptionsNotReasonablyCertainToExerciseMembersrt:MinimumMember2021-09-300001337013srt:MaximumMemberinfu:OfficeLeasesWithRenewalOptionsNotReasonablyCertainToExerciseMember2021-09-300001337013us-gaap:OperatingSegmentsMemberinfu:ITSSegmentMember2021-07-012021-09-300001337013us-gaap:OperatingSegmentsMemberinfu:DMEServicesSegmentMember2021-07-012021-09-300001337013infu:CorporateAndEliminationsMember2021-07-012021-09-300001337013us-gaap:OperatingSegmentsMemberinfu:ITSSegmentMember2021-09-300001337013us-gaap:OperatingSegmentsMemberinfu:DMEServicesSegmentMember2021-09-300001337013infu:CorporateAndEliminationsMember2021-09-300001337013us-gaap:OperatingSegmentsMemberinfu:ITSSegmentMember2020-07-012020-09-300001337013us-gaap:OperatingSegmentsMemberinfu:DMEServicesSegmentMember2020-07-012020-09-300001337013infu:CorporateAndEliminationsMember2020-07-012020-09-300001337013us-gaap:OperatingSegmentsMemberinfu:ITSSegmentMember2020-09-300001337013us-gaap:OperatingSegmentsMemberinfu:DMEServicesSegmentMember2020-09-300001337013infu:CorporateAndEliminationsMember2020-09-300001337013us-gaap:OperatingSegmentsMemberinfu:ITSSegmentMember2021-01-012021-09-300001337013us-gaap:OperatingSegmentsMemberinfu:DMEServicesSegmentMember2021-01-012021-09-300001337013infu:CorporateAndEliminationsMember2021-01-012021-09-300001337013us-gaap:OperatingSegmentsMemberinfu:ITSSegmentMember2020-01-012020-09-300001337013us-gaap:OperatingSegmentsMemberinfu:DMEServicesSegmentMember2020-01-012020-09-300001337013infu:CorporateAndEliminationsMember2020-01-012020-09-30

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

x    Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

for the quarterly period ended September 30, 2021

or

¨     Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

for the transition period from _____ to _____

Commission File Number: 001-35020

INFUSYSTEM HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware			20-3341405
(State or Other Jurisdiction of  Incorporation or Organization)			(I.R.S. Employer  Identification No.)

3851 West Hamlin Road

Rochester Hills, Michigan 48309

(Address of Principal Executive Offices)

Registrant’s Telephone Number, including Area Code: (248) 291-1210

Securities Registered Pursuant to Section 12(b) of the Act:

Title of Each Class			Trading Symbol(s)			Name of Each Exchange on which Registered
Common Stock, par value $0.0001 per share			INFU			NYSE American LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

¨

Accelerated filer

¨

Non-accelerated filer

x

Smaller reporting company

x

Emerging growth company

¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

As of November 10, 2021, 20,649,447 shares of the registrant’s common stock, par value $0.0001 per share, were outstanding.

1

---

Table of Contents

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

Index to Form 10-Q

						PAGE
PART I -			FINANCIAL INFORMATION
Item 1.			Financial Statements			3
			-Unaudited Condensed Consolidated Balance Sheets as of September 30, 2021 and December 31, 2020			3
			-Unaudited Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income for the three and nine months ended September 30, 2021 and 2020			4
			-Unaudited Condensed Consolidated Statements of Stockholders’ Equity for the three and nine months ended September 30, 2021 and 2020			5
			-Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2021 and 2020			6
			-Notes to the Unaudited Condensed Consolidated Financial Statements			7
Item 2.			Management’s Discussion and Analysis of Financial Condition and Results of Operations			21
Item 3.			Quantitative and Qualitative Disclosures About Market Risk			32
Item 4.			Controls and Procedures			32
PART II -			OTHER INFORMATION
Item 1.			Legal Proceedings			32
Item 1A.			Risk Factors			33
Item 2.			Unregistered Sales of Equity Securities and Use of Proceeds			33
Item 3.			Defaults Upon Senior Securities			33
Item 4.			Mine Safety Disclosures			33
Item 5.			Other Information			33
Item 6.			Exhibits			34
			Signatures			35

2

---

Table of Contents

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

			As of
(in thousands, except par value and share data)			September 30, 2021						December 31, 2020
ASSETS
Current assets:
Cash and cash equivalents			$	165					$	9,648
Accounts receivable, net			15,845						14,720
Inventories			3,705						3,001
Other current assets			2,151						2,402
Total current assets			21,866						29,771
Medical equipment for sale or rental			1,540						1,603
Medical equipment in rental service, net of accumulated depreciation			36,431						35,611
Property & equipment, net of accumulated depreciation			4,426						4,296
Goodwill			3,710						—
Intangible assets, net			11,928						11,177
Operating lease right of use assets			3,859						4,461
Deferred income taxes			10,819						9,967
Other assets			207						105
Total assets			$	94,786					$	96,991
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable			$	6,703					$	6,779
Current portion of long-term debt			336						9,423
Other current liabilities			7,446						6,795
Total current liabilities			14,485						22,997
Long-term debt, net of current portion			30,559						29,378
Operating lease liabilities, net of current portion			3,287						3,864
Total liabilities			48,331						56,239
Stockholders’ equity:
Preferred stock, $0.0001 par value: authorized 1,000,000 shares; none issued			—						—
Common stock, $0.0001 par value: authorized 200,000,000 shares; issued and outstanding 24,125,687 and 20,607,198, respectively, as of September 30, 2021, and issued and outstanding 23,816,193 and 20,297,704, respectively, as of December 31, 2020			2						2
Additional paid-in capital			89,385						84,785
Accumulated other comprehensive income			70						—
Retained deficit			(43,002)						(44,035)
Total stockholders’ equity			46,455						40,752
Total liabilities and stockholders’ equity			$	94,786					$	96,991

See accompanying notes to unaudited condensed consolidated financial statements.

3

---

Table of Contents

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME

(UNAUDITED)

(in thousands, except share and per share data)			Three Months Ended September 30,												Nine Months Ended September 30,
			2021						2020						2021						2020
Net revenues			$	26,566					$	25,125					$	75,863					$	72,677
Cost of revenues			11,308						10,003						30,979						28,914
Gross profit			15,258						15,122						44,884						43,763
Selling, general and administrative expenses:
Provision for doubtful accounts			10						11						(99)						534
Amortization of intangibles			1,125						1,075						3,264						3,225
Selling and marketing			2,908						2,196						7,964						7,263
General and administrative			11,566						8,587						32,537						24,949
Total selling, general and administrative			15,609						11,869						43,666						35,971
Operating (loss) income			(351)						3,253						1,218						7,792
Other expense:
Interest expense			(270)						(283)						(909)						(1,018)
Other (expense) income			(44)						8						(150)						(20)
(Loss) Income before income taxes			(665)						2,978						159						6,754
Benefit from (provision for) income taxes			217						(38)						874						(92)
Net (loss) income			$	(448)					$	2,940					$	1,033					$	6,662
Net (loss) income per share
Basic			$	(0.02)					$	0.15					$	0.05					$	0.33
Diluted			$	(0.02)					$	0.14					$	0.05					$	0.31
Weighted average shares outstanding:
Basic			20,577,886						20,179,056						20,468,842						20,060,416
Diluted			20,577,886						21,663,414						21,995,216						21,637,481
Comprehensive income:
Net (loss) income			$	(448)					$	2,940					$	1,033					$	6,662
Other comprehensive income:
Unrealized gain on hedges			41						—						93						—
Provision for income tax on unrealized hedge gain			(10)						—						(23)						—
Net comprehensive (loss) income			$	(417)					$	2,940					$	1,103					$	6,662

See accompanying notes to unaudited condensed consolidated financial statements.

4

---

Table of Contents

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF

STOCKHOLDERS’ EQUITY

(UNAUDITED)

						Common Stock												Additional Paid in Capital						Retained Deficit						Accumulated Other Comprehensive Income						Treasury Stock												Total Stockholders’ Equity
(in thousands)						Shares						Par Value Amount																								Shares						Par Value Amount
Balances at June 30, 2020						23,651						$	2					$	83,845					$	(57,645)					$	—					(3,518)						$	—					$	26,202
Stock-based shares issued upon vesting - gross						127						—						—						—						—						—						—						—
Stock-based compensation expense						—						—						659						—						—						—						—						659
Employee stock purchase plan						15						—						116						—						—						—						—						116
Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation						(38)						—						(528)						—						—						—						—						(528)
Net income						—						—						—						2,940						—						—						—						2,940
Balances at September 30, 2020						23,755						$	2					$	84,092					$	(54,705)					$	—					(3,518)						$	—					$	29,389
Balances at June 30, 2021						24,084						$	2					$	87,213					$	(42,554)					$	39					(3,518)						$	—					$	44,700
Stock-based shares issued upon vesting - gross						25						—						38						—						—						—						—						38
Stock-based compensation expense						—						—						1,955						—						—						—						—						1,955
Employee stock purchase plan						16						—						179						—						—						—						—						179
Other comprehensive income						—						—						—						—						31						—						—						31
Net loss						—						—						—						(448)						—						—						—						(448)
Balances at September 30, 2021						24,125						$	2					$	89,385					$	(43,002)					$	70					(3,518)						$	—					$	46,455
Balances at December 31, 2019						23,401						$	2					$	83,699					$	(61,367)					$	—					(3,518)						$	—					$	22,334
Stock-based shares issued upon vesting - gross						419						—						—						—						—						—						—						—
Stock-based compensation expense						—						—						1,222						—						—						—						—						1,222
Employee stock purchase plan						29						—						190						—						—						—						—						190
Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation						(122)						—						(1,269)						—						—						—						—						(1,269)
Common stock issued						28						—						250						—						—						—						—						250
Net income						—						—						—						6,662						—						—						—						6,662
Balances at September 30, 2020						23,755						$	2					$	84,092					$	(54,705)					$	—					(3,518)						$	—					$	29,389
Balances at December 31, 2020						23,816						$	2					$	84,785					$	(44,035)					$	—					(3,518)						$	—					$	40,752
Stock-based shares issued upon vesting - gross						334						—						431						—						—						—						—						431
Stock-based compensation expense						—						—						4,962						—						—						—						—						4,962
Employee stock purchase plan						32						—						348						—						—						—						—						348
Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation						(57)						—						(1,141)						—						—						—						—						(1,141)
Other comprehensive income						—						—						—						—						70						—						—						70
Net income						—						—						—						1,033						—						—						—						1,033
Balances at September 30, 2021						24,125						$	2					$	89,385					$	(43,002)					$	70					(3,518)						$	—					$	46,455

See accompanying notes to unaudited condensed consolidated financial statements.

5

---

Table of Contents

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

			Nine Months Ended September 30,
(in thousands)			2021						2020
OPERATING ACTIVITIES
Net income			$	1,033					$	6,662
Adjustments to reconcile net income to net cash provided by operating activities:
Provision for doubtful accounts			(99)						534
Depreciation			7,705						7,267
Loss on disposal of and reserve adjustments for medical equipment			848						150
Gain on sale of medical equipment			(1,588)						(2,949)
Amortization of intangible assets			3,264						3,225
Amortization of deferred debt issuance costs			132						13
Stock-based compensation			4,962						1,222
Deferred income taxes			(875)						16
Changes in assets - (increase)/decrease:
Accounts receivable			217						(1,490)
Inventories			(630)						(1,074)
Other current assets			251						75
Other assets			(102)						(114)
Changes in liabilities - (decrease)/increase:
Accounts payable and other liabilities			(513)						(869)
NET CASH PROVIDED BY OPERATING ACTIVITIES			14,605						12,668
INVESTING ACTIVITIES
Acquisition of business			(7,650)						—
Purchase of medical equipment			(9,645)						(11,955)
Purchase of property and equipment			(607)						(865)
Proceeds from sale of medical equipment, property and equipment			2,214						3,870
NET CASH USED IN INVESTING ACTIVITIES			(15,688)						(8,950)
FINANCING ACTIVITIES
Principal payments on long-term debt			(69,306)						(35,458)
Cash proceeds from long-term debt			61,654						31,861
Debt issuance costs			(386)						—
Common stock repurchased to satisfy statutory withholding on employee stock-based compensation plans			(1,141)						(1,269)
Cash proceeds from stock plans			779						190
Common stock - issued			—						250
NET CASH USED IN FINANCING ACTIVITIES			(8,400)						(4,426)
Net change in cash and cash equivalents			(9,483)						(708)
Cash and cash equivalents, beginning of period			9,648						2,647
Cash and cash equivalents, end of period			$	165					$	1,939

See accompanying notes to unaudited condensed consolidated financial statements.

6

---

Table of Contents

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1.Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies

The terms “InfuSystem”, the “Company”, “we”, “our” and “us” are used herein to refer to InfuSystem Holdings, Inc. and its subsidiaries. InfuSystem is a leading provider of infusion pumps and related products and services for patients in the home, oncology clinics, ambulatory surgery centers, and other sites of care. The Company provides products and services to hospitals, oncology practices and facilities and other alternative site health care providers. Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support, and also operates pump service and repair Centers of Excellence in Michigan, Kansas, California, Massachusetts, Texas and Ontario, Canada.

The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, the unaudited condensed consolidated financial statements do not include all of the information and notes required by U.S. Generally Accepted Accounting Principles (“GAAP”) for complete financial statements. The accompanying unaudited condensed consolidated financial statements include all adjustments, composed of normal recurring adjustments, considered necessary by management to fairly state the Company’s results of operations, financial position and cash flows. The operating results for the interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the SEC on March 22, 2021.

The unaudited condensed consolidated financial statements are prepared in conformity with GAAP, which requires the use of estimates, judgments and assumptions that affect the amounts of assets and liabilities at the reporting date and the amounts of revenue and expenses in the periods presented. The Company believes that the accounting estimates employed are appropriate and the resulting balances are reasonable; however, due to the inherent uncertainties in making estimates, actual results could differ from the original estimates, requiring adjustments to these balances in future periods.

Derivatives Accounting Policy

The Company recognizes all derivative financial instruments as cash flow hedges which are shown as either assets or liabilities on the Company’s consolidated balance sheets at fair value. For derivative contracts which can be classified as a cash flow hedge, the effective portion of the change in fair value of the derivative is recorded to accumulated other comprehensive income (“AOCI”) in the consolidated balance sheets. The underlying hedge transaction is realized when the interest payments on debt are accrued; the applicable amount of gain or loss included in AOCI is reclassified into earnings in the consolidated statements of operations on the same line as the gain or loss on the hedged item attributable to the hedged risk. The cash flows from derivatives are classified as operating activities.

The Company maintains a policy of requiring that all derivative instruments be governed by an International Swaps and Derivatives Association Master Agreement and settles on a net basis.

The fair values of the Company’s derivative financial instruments are categorized as Level 2 of the fair value hierarchy as the values are derived using the market approach based on observable market inputs including quoted prices of similar instruments and interest rate forward curves.

2.Recent Accounting Pronouncements and Developments

In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2016-13, “Financial Instruments (Topic 326) Credit Losses”. Topic 326 changes the impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial assets and net investment in leases that are not accounted for at fair value through net income are to be presented at the net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. Topic 326 was originally effective as of January 1, 2020, although in November 2019, the FASB delayed the effective date until fiscal years beginning after December 15, 2022 for SEC filers eligible to be smaller reporting companies under the SEC’s definition. The Company qualifies as a smaller reporting company under the SEC’s definition. Early adoption is permitted. The Company is currently evaluating the impact of Topic 326 on its consolidated balance sheets, statements of operations, statements of cash flows and related disclosures.

7

---

Table of Contents

3.Business Combinations

Acquisitions Accounted for Using the Purchase Method

On January 31, 2021, the Company closed on the acquisition of substantially all of the assets of FilAMed, a privately-held biomedical services company based in Bakersfield, California. This acquisition will supplement the Company’s existing biomedical recertification, maintenance and repair services for acute care facilities and other alternate site settings including home care and home infusion providers, skilled nursing facilities, pain centers and others.

On April 18, 2021, the Company acquired the business and substantially all of the assets of OB Healthcare Corporation (“OB Healthcare”), a privately-held biomedical services company based in Austin, Texas. OB Healthcare specializes in on-site repair, preventative maintenance, and device physical inventory management to hospitals and healthcare systems nationwide. The acquisition further develops and expands InfuSystem’s Durable Medical Equipment Services (“DME Services”) segment and complements the Company’s purchase of FilAMed.

FilAMed and OB Healthcare’s results of operations are included in the Company’s consolidated statements of operations from the respective closing dates. Revenues and earnings from these acquisitions have not been significant through September 30, 2021.

Purchase Price Allocation

Pursuant to FASB Accounting Standards Codification (“ASC”) Topic 805, “Business Combinations,” the purchase price for each of the acquisitions was allocated to the assets acquired and liabilities assumed based upon their estimated fair values as of the respective acquisition dates. The purchase price allocations were primarily based upon a valuation using management’s estimates and assumptions. The purchase price allocation was completed for FilAMed as of September 30, 2021. The purchase price allocation for OB Healthcare was based on a preliminary analysis and is subject to further adjustments related to the final working capital determination. Upon completion of the final purchase price allocation, the Company may need to adjust the accounts receivable. The following table summarizes the consideration paid and the allocation of the purchase price to the fair values of the assets acquired and liabilities assumed as of the respective acquisition dates for both FilAMed and OB Healthcare (in thousands):

			FilAMed						OB Healthcare						Total Consideration
Cash			$	1,400					$	6,250					$	7,650
Working capital (a)			—						327						327
Contingent consideration			—						750						750
Total - consideration			$	1,400					$	7,327					$	8,727

						FilAMed						OB Healthcare						Total Acquisition Date Fair Value
Accounts receivable (a)						$	—					$	727					$	727
Inventories						74						—						74
Medical equipment held for sale or rental						40						—						40
Property and equipment						102						59						161
Intangible assets						1,015						3,000						4,015
Goodwill						169						3,541						3,710
Operating lease right of use assets						281						7						288
Operating lease liabilities						(281)						(7)						(288)
Total - purchase price (a)						$	1,400					$	7,327					$	8,727
(a) Amount based on preliminary working capital.

8

---

Table of Contents

The amount of acquisition costs for both transactions was $0.2 million and is included in general and administrative expenses for the nine months ended September 30, 2021.

During the three months ended September 30, 2021, the Company updated the valuation of OB Healthcare based on further analysis of the final working capital with an immaterial decrease in the consideration transferred and a corresponding decrease to goodwill. There was no impact to the condensed consolidated statement of operations.

The Company fully paid all consideration for FilAMed as of September 30, 2021. On the OB Healthcare acquisition date, the Company made an initial cash payment of $6.1 million with a subsequent cash payment of $0.1 million during the quarter ended September 30, 2021 and had an additional estimated amount due to the seller of $0.3 million, related to a working capital adjustment, and contingent consideration of $0.8 million, both of which were recorded in the balance sheet under the heading for other current liabilities. The contingent consideration arrangement requires the Company to pay OB Healthcare $0.8 million if certain written contracts are executed by December 31, 2021. The Company expects OB Healthcare to satisfy this requirement. As of September 30, 2021, the Company had a $1.1 million remaining liability relating to this acquisition.

The following table shows the breakdown of the identified intangible assets acquired into major intangible asset classes for both acquisitions:

						Acquisition Date Fair Value (Thousands)						Weighted-Average Amortization Period (Years)
Customer relationships						$	2,300					15
Unpatented technology						943						7
Non-competition agreements						472						5
Internal-use software						300						5
Total intangible assets (a)						$	4,015					11.2
(a) There was no residual value, renewal terms or extensions associated with any intangible assets acquired.

The goodwill acquired consists of expected synergies from combining operations of FilAMed and OB Healthcare with the DME Services segment as well as their respective assembled workforce who have specialized knowledge and experience. All of the goodwill is deductible for tax purposes.

Unaudited Pro Forma Financial Information

The unaudited pro forma financial information in the table below summarizes the combined results of operations of the Company, FilAMed and OB Healthcare as though the companies’ businesses had been combined as of January 1, 2020. The pro forma financial information for the three and nine months ended September 30, 2021 has been adjusted by $0.1 million and $0.2 million, respectively, for the tax effected amount of acquisition costs and non-recurring expenses directly attributable to the FilAMed and OB Healthcare acquisitions. The three and nine months ended September 30, 2020 also included these charges. The pro forma financial information is presented for informational purposes only and is not indicative of the results of operations that would have been achieved if the acquisitions had taken place at the beginning of each period presented nor is it indicative of future results. The following pro forma financial information presented also includes the pro forma depreciation

9

---

Table of Contents

and amortization charges from acquired tangible and intangible assets for the three and nine months ended September 30, 2021 and 2020 (in thousands):

			Three Months Ended September 30,												Nine Months Ended September 30,
			2021						2020						2021						2020
Revenue			$	26,566					$	25,731					$	76,633					$	75,270
Net income			$	(373)					$	2,691					$	1,268					$	6,120

4.Revenue Recognition

The following table presents the Company’s disaggregated revenue by offering type (in thousands):

			Three Months Ended September 30,
			2021												2020
			Total Net Revenues						Percentage of Total Net Revenues						Total Net Revenues						Percentage of Total Net Revenues
Third-Party Payer Rentals			$	13,512					50.9		%				$	12,672					50.4		%
Direct Payer Rentals			8,655						32.6		%				7,933						31.6		%
Product Sales			4,399						16.5		%				4,520						18.0		%
Total			$	26,566					100.0		%				$	25,125					100.0		%

			Nine Months Ended September 30,
			2021												2020
			Total Net Revenues						Percentage of Total Net Revenues						Total Net Revenues						Percentage of Total Net Revenues
Third-Party Payer Rentals			$	39,436					52.0		%				$	36,660					50.4		%
Direct Payer Rentals			25,095						33.1		%				22,733						31.3		%
Product Sales			11,332						14.9		%				13,284						18.3		%
Total			$	75,863					100.0		%				$	72,677					100.0		%

Third-Party Payer Rentals are entirely attributed to revenues of the Integrated Therapy Services (“ITS”) segment. Product Sales are entirely attributed to revenues of the DME Services segment. For the three months ended September 30, 2021, $3.1 million and $5.6 million of Direct Payer Rentals were attributed to the ITS and DME Services segments, respectively. For the three months ended September 30, 2020, $3.0 million and $4.9 million of Direct Payer Rentals were attributed to the ITS and DME Services segments, respectively.

For the nine months ended September 30, 2021, $9.4 million and $15.7 million of Direct Payer Rentals were attributed to the ITS and DME Services segments, respectively. For the nine months ended September 30, 2020, $8.7 million and $14.0 million of Direct Payer Rentals were attributed to the ITS and DME Services segments, respectively.

10

---

Table of Contents

5.Medical Equipment

Medical equipment consisted of the following (in thousands):

			September 30, 2021						December 31, 2020
Medical equipment for sale or rental			$	1,592					$	1,636
Medical equipment for sale or rental - pump reserve			(52)						(33)
Medical equipment for sale or rental - net			1,540						1,603
Medical equipment in rental service			88,107						83,411
Medical equipment in rental service - pump reserve			(1,356)						(893)
Accumulated depreciation			(50,320)						(46,907)
Medical equipment in rental service - net			36,431						35,611
Total			$	37,971					$	37,214

Depreciation expense for medical equipment for the three and nine months ended September 30, 2021 was $2.4 million and $7.0 million, respectively, compared to $2.3 million and $6.7 million for the same prior year periods, respectively. This expense was recorded in “cost of revenues” for each period.

6.Property and Equipment

Property and equipment consisted of the following (in thousands):

			September 30, 2021																		December 31, 2020
			Gross Assets						Accumulated Depreciation						Total						Gross Assets						Accumulated Depreciation						Total
Furniture, fixtures, and equipment			$	4,535					$	(2,411)					$	2,124					$	3,742					$	(2,018)					$	1,724
Automobiles			117						(110)						7						117						(102)						15
Leasehold improvements			3,418						(1,123)						2,295						3,416						(859)						2,557
Total			$	8,070					$	(3,644)					$	4,426					$	7,275					$	(2,979)					$	4,296

Depreciation expense for property and equipment for the three and nine months ended September 30, 2021 was $0.2 million and $0.7 million, respectively, compared to $0.2 million and $0.6 million for the same prior year periods, respectively. This expense was recorded in “general and administrative expenses” for each period.

11

---

Table of Contents

7.Goodwill & Intangible Assets

The changes in the carrying value of goodwill by segment for the nine months ended September 30, 2021 are as follows (in thousands):

						DME Services (a)
Balance as of December 31, 2020						$	—
Goodwill acquired						3,710
Balance as of September 30, 2021						$	3,710
(a) No goodwill allocated to the ITS segment.

The carrying amount and accumulated amortization of intangible assets consisted of the following (in thousands):

			September 30, 2021																		December 31, 2020
			Gross Assets						Accumulated Amortization						Net						Gross Assets						Accumulated Amortization						Net
Nonamortizable intangible assets
Trade names			$	2,000											$	2,000					$	2,000					$	—					$	2,000
Amortizable intangible assets:
Trade names			23						(23)						—						23						(23)						—
Physician and customer relationships			38,834						(30,769)						8,065						36,534						(28,924)						7,610
Non-competition agreements			472						(43)						429						—						—						—
Unpatented technology			943						(90)						853						—						—						—
Software			11,530						(10,949)						581						11,230						(9,663)						1,567
Total nonamortizable and amortizable intangible assets			$	53,802					$	(41,874)					$	11,928					$	49,787					$	(38,610)					$	11,177

Amortization expense for the three and nine months ended September 30, 2021 was $1.1 million and $3.3 million, respectively, compared to $1.1 million and $3.2 million for the same prior year periods, respectively. This expense was recorded in “amortization of intangibles expenses” for each period. Expected remaining annual amortization expense for the next five years for intangible assets recorded as of September 30, 2021 is as follows (in thousands):

			2021						2022						2023						2024						2025						2026 and thereafter						Total
Amortization expense			$	998					$	2,494					$	990					$	990					$	810					$	3,646					$	9,928

8.Debt

On February 5, 2021, the Company entered into a Credit Agreement (the “2021 Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent (the “Agent”), sole bookrunner and sole lead arranger, and the lenders party thereto. The borrowers under the 2021 Credit Agreement are the Company, InfuSystem Holdings USA, Inc. (“Holdings”), InfuSystem,

12

---

Table of Contents

Inc. (“ISI”), First Biomedical, Inc. (“First Biomedical”), and IFC LLC (“IFC” and, collectively with the Company, Holdings, ISI and First Biomedical, the “Borrowers”).

The 2021 Credit Agreement provides for a revolving credit facility (the “Revolving Facility”) of $75.0 million, maturing on February 5, 2026. The Revolving Facility may be increased by $25.0 million, subject to certain conditions, including the consent of the Agent and obtaining necessary commitments. The lenders under the 2021 Credit Agreement may issue up to $7.0 million in letters of credit subject to the satisfaction of certain conditions. On February 5, 2021, the Borrowers made an initial borrowing of $30.0 million under the Revolving Facility. Proceeds from the loan, along with approximately $8.2 million in cash, were used to repay all amounts due under the Company’s then existing credit facility dated March 23, 2015 (the “2015 Credit Agreement”).

The 2021 Credit Agreement has customary representations and warranties. The ability to borrow under the facility is subject to ongoing compliance with a number of customary affirmative and negative covenants, including limitations on indebtedness, liens, mergers, acquisitions, investments, asset sales, affiliate transactions and restricted payments, as well as financial covenants, including the following:

•a minimum fixed charge coverage ratio (defined as the ratio of consolidated EBITDA (as defined in the 2021 Credit Agreement) less 50% of depreciation expense), to consolidated fixed charges (as defined in the 2021 Credit Agreement)) for the prior four most recently ended calendar quarters of 1.20 to 1.00; and

•a maximum leverage ratio (defined as total indebtedness to EBITDA for the prior four most recently ended calendar quarters) of 3.50 to 1.00.

The 2021 Credit Agreement includes customary events of default. The occurrence of an event of default will permit the lenders to terminate commitments to lend under the Revolving Facility and accelerate payment of all amounts outstanding thereunder.

Simultaneous with the execution of the 2021 Credit Agreement, the Company entered into a Pledge and Security Agreement to secure repayment of the obligations of the Borrowers. Under the Pledge and Security Agreement, each Borrower has granted to the Agent, for the benefit of various secured parties, a first priority security interest in substantially all of the personal property assets of each of the Borrowers, including the shares of each of Holdings, ISI and First Biomedical and the equity interests of IFC.

On February 5, 2021, in connection with the execution and closing of the 2021 Credit Agreement, the Company, along with its wholly owned subsidiaries as borrowers, terminated the 2015 Credit Agreement. All outstanding loans under the 2015 Credit Agreement have been repaid and all liens under the 2015 Credit Agreement have been released, except that a letter of credit originally issued under the 2015 Credit Agreement in the amount of approximately $0.8 million was transferred to the 2021 Credit Agreement.

At December 31, 2020, the 2015 Credit Agreement, which would have matured on November 9, 2024, included three term notes totaling $37.9 million, with varying required quarterly amortization payments, and an undrawn $11.8 million revolving line of credit. The availability under the line of credit was reduced by outstanding letters of credit and reserves totaling $1.0 million and was subject to a borrowing base limitation as defined by the agreement. The borrowing base was approximately $15.6 million at December 31, 2020. At December 31, 2020 and on the date of the refinancing, the Company was in compliance with all affirmative and negative covenants, as outlined in the agreement, which included maintenance of a maximum leverage ratio and a minimum fixed charge coverage ratio, as defined in the agreement. Interest on the facility was payable at the Company’s option as a (i) Eurodollar Loan, which bore interest at a per annum rate equal to the applicable 30-day LIBOR plus an applicable margin ranging from 2.00% to 3.00% or (ii) CB Floating Rate (“CBFR”) Loan, which bore interest at a per annum rate equal to the greater of (a) the lender’s prime rate or (b) LIBOR plus 2.50%, in each case, plus a margin ranging from -1.00% to 0.25% based on our leverage ratio. The actual Eurodollar Loan rate at December 31, 2020 was 2.19% (LIBOR of 0.19% plus 2.00%). The actual CBFR Loan rate at December 31, 2020 was 2.25% (lender’s prime rate of 3.25% minus 1.00%).

The 2021 Credit Agreement was accounted for as a debt modification. As of September 30, 2021, the Company was in compliance with all debt-related covenants under the 2021 Credit Agreement.

On April 15, 2019, the Company sold for $2.0 million and immediately leased back certain medical equipment in rental service to a third party specializing in such transactions. The leaseback term is 36 months. Because the arrangement contains a purchase option that the Company is reasonably certain to exercise, this transaction did not qualify for the sale-leaseback accounting under ASC 842. The medical equipment remains recorded on the accompanying condensed consolidated balance

13

---

Table of Contents

sheet and the proceeds received have been classified as an other financing liability, which is being paid off monthly over the term of the lease. The balance of other financing as of September 30, 2021 was $0.4 million.

As referenced above, the Company executed and closed the 2021 Credit Agreement during the first quarter of 2021, and in connection with entering into that agreement, terminated the 2015 Credit Agreement. For the following tables, the figures related to the September 30, 2021 revolving credit facility balances relate to the 2021 Credit Agreement, while the December 31, 2020 revolving credit facility balances relate to the now-terminated 2015 Credit Agreement. The following table illustrates the net availability under the revolving credit facilities as of the applicable balance sheet date (in thousands):

			September 30, 2021						December 31, 2020
Revolving Facility:
Gross availability			$	75,000					$	11,750
Outstanding draws			(30,804)						—
Letter of credit			(800)						(800)
Landlord reserves			—						(162)
Availability on Revolving Facility			$	43,396					$	10,788

The Company had future maturities of its long-term debt as of September 30, 2021 as follows (in thousands):

			2021						2022						2023						2024						2025 and thereafter						Total
Revolving Facility			$	—					$	—					$	—					$	—					$	30,804					$	30,804
Other financing			188						222						—						—						—						410
Total			$	188					$	222					$	—					$	—					$	30,804					$	31,214

The following is a breakdown of the Company’s current and long-term debt (in thousands):

			September 30, 2021																		December 31, 2020
			Current Portion						Long-Term Portion						Total						Current Portion						Long-Term Portion						Total
Revolving Facility			$	—					$	30,804					$	30,804					$	—					$	—					$	—
Term loan			—						—						—						4,615						17,305						21,920
Equipment line			—						—						—						1,600						4,400						6,000
2019 equipment line			—						—						—						2,500						7,500						10,000
Other financing			410						—						410						725						222						947
			410						30,804						31,214						9,440						29,427						38,867
Unamortized value of debt issuance costs			(74)						(245)						(319)						(17)						(49)						(66)
Total			$	336					$	30,559					$	30,895					$	9,423					$	29,378					$	38,801

As of September 30, 2021, amounts outstanding under the Revolving Facility provided under the 2021 Credit Agreement bear interest at a variable rate equal to, at the Company’s election, a LIBO Rate for Eurodollar loans or an Alternative Base Rate for ABR loans, as defined by the 2021 Credit Agreement, plus a spread that will vary depending upon the Company’s leverage ratio. The spread ranges from 2.00% to 3.00% for Eurodollar Loans and 1.00% to 2.00% for base rate loans. The weighted-average Eurodollar loan rate at September 30, 2021 was 2.09% (LIBO of 0.09% plus 2.00%). The actual ABR loan rate at September 30, 2021 was 4.25% (lender’s prime rate of 3.25% plus 1.00%).

9.Derivative Financial Instruments and Hedging Activities

14

---

Table of Contents

During the quarter ended March 31, 2021, the Company adopted a derivative investment policy which provides guidelines and objectives related to managing financial and operational exposures arising from market changes in short term interest rates. In accordance with this policy, the Company can enter into interest rate swaps or similar instruments, will endeavor to evaluate all the risks inherent in a transaction before entering into a derivative financial instrument and will not enter into derivative financial instruments for speculative or trading purposes. Hedging relationships are formally documented at the inception of the hedge and hedges must be highly effective in offsetting changes to future cash flows on hedged transactions at the inception of a hedge and on an ongoing basis to be designated for hedge accounting treatment.

The Company is exposed to interest rate risk related to its variable rate debt obligations under the 2021 Credit Agreement. In order to manage the volatility in interest rate markets, in February 2021, the Company entered into two interest rate swap agreements to manage exposure arising from this risk. On a combined basis, the agreements have a constant notional amount over a five-year term that ends on February 5, 2026. The agreements both pay the Company 30-day LIBOR on the notional amount and the Company pays a fixed rate of interest equal to 0.73%. These derivative instruments are considered cash flow hedges. The Company does not have any other derivative financial instruments.

The table below presents the location and gross fair value amounts of our derivative financial instruments and the associated notional amounts designated as cash flow hedges (in thousands):

September 30, 2021 (a)

Balance Sheet Location

Notional

Fair Value Derivative Assets

Derivatives designated as hedges:

Cash flow hedges

Interest rate swaps

Other assets

$

20,000

$

93

(a) No derivative instruments existed at December 31, 2020.

The table below presents the effect of our derivative financial instruments designated as hedging instruments in AOCI (in thousands):

						Three Months Ended September 30, 2021 (a)						Nine Months Ended September 30, 2021 (a)
Gain on cash flow hedges - interest rate swaps
Beginning balance						$	39					$	—
Unrealized gain recognized in AOCI						9						20
Amounts reclassified to interest expense (b)(c)						32						73
Tax provision						(10)						(23)
Ending balance						$	70					$	70
(a) No derivative instruments existed for the three and nine months ended September 30, 2020.
(b) Positive amounts represented interest expense. Total interest expense as presented in the consolidated statement of operations for the three and nine months ended September 30, 2021 were $0.3 million and $0.9 million, respectively.
(c) $0.1 million of expense is expected to be reclassified into earnings within the next 12 months.

The Company did not incur any hedge ineffectiveness during the three or nine months ended September 30, 2021.

10.Income Taxes

During the three and nine months ended September 30, 2021, the Company recorded a benefit from income taxes of $0.2 million and $0.9 million, respectively. The income tax benefit relates principally to excess tax benefits on exercises of stock options and vesting of restricted stock during the periods offset by the estimate of the Company’s annual state and local taxes and taxes relating to its foreign operations in Canada. For both the three and nine months ended September 30, 2020, the Company recorded provision for income taxes of less than $0.1 million.

15

---

Table of Contents

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act was enacted in response to the COVID-19 pandemic. The CARES Act among other things, allows employers to defer the deposit and payment of the employer's share of Social Security taxes. Under the CARES Act, the Company deferred paying $0.7 million of applicable gross payroll taxes, which is included in other current liabilities as of September 30, 2021. The $0.7 million balance of the deferred Social Security taxes is expected to be paid in two equal annual installments during the years ending December 31, 2021 and 2022, respectively.

11.Commitments, Contingencies and Litigation

From time to time in the ordinary course of its business, the Company may be involved in legal and regulatory proceedings, the outcomes of which may not be determinable. The results of litigation and regulatory proceedings are inherently unpredictable. Any claims against the Company, whether meritorious or not, could be time consuming, result in costly litigation, require significant amounts of management time and result in diversion of significant resources. The Company is not able to estimate an aggregate amount or range of reasonably possible losses for those legal matters for which losses are not probable and estimable, primarily for the following reasons: (i) many of the relevant legal proceedings are in preliminary stages and, until such proceedings develop further, there is often uncertainty regarding the relevant facts and circumstances at issue and potential liability; and (ii) many of these proceedings involve matters of which the outcomes are inherently difficult to predict. The Company has insurance policies covering potential losses where such coverage is cost effective.

The Company is not at this time involved in any proceedings that the Company currently believes could have a material effect on the Company’s financial condition, results of operations or cash flows.

12.Earnings Per Share

Basic income per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted income per share assumes the issuance of potentially dilutive shares of common stock during the period. The following table reconciles the numerators and denominators of the basic and diluted income per share computations:

			Three Months Ended September 30,												Nine Months Ended September 30,
Numerator (in thousands):			2021						2020						2021						2020
Net (loss) income:			$	(448)					$	2,940					$	1,033					$	6,662
Denominator:
Weighted average common shares outstanding:
Basic			20,577,886						20,179,056						20,468,842						20,060,416
Dilutive effect of common stock equivalents			—						1,484,358						1,526,374						1,577,065
Diluted			20,577,886						21,663,414						21,995,216						21,637,481
Net (loss) income per share:
Basic			$	(0.02)					$	0.15					$	0.05					$	0.33
Diluted			$	(0.02)					$	0.14					$	0.05					$	0.31

For the three months ended September 30, 2021, all outstanding options and restricted stock units were anti-dilutive due to the Company's net losses for the period and therefore are not included in the calculation. For the nine months ended September 30, 2021, 0.3 million of outstanding options and restricted stock units with an exercise price above the current market value of the Company’s common stock were not included in the calculation because they would have an anti-dilutive effect. For both the three and nine months ended September 30, 2020, less than 0.1 million of outstanding options and restricted stock units with an exercise price above the current market value of the Company’s common stock were not included in the calculation because they would have an anti-dilutive effect.

Share Repurchase Program

On June 30, 2021, our Board of Directors approved a stock repurchase program (the “Share Repurchase Program”) authorizing the Company to repurchase up to $20.0 million of the Company’s outstanding common stock through June 30, 2024. The repurchase program will be subject to market conditions, the periodic capital needs of the Company’s operating activities, and the continued satisfaction of all covenants under the Company’s existing 2021 Credit Agreement. Repurchases under the program may take place in the open market or in privately negotiated transactions and may be made under a Rule

16

---

Table of Contents

10b5-1 plan. The repurchase program does not obligate the Company to repurchase shares and may be suspended, terminated, or modified at any time. As of September 30, 2021, the Company had not repurchased any shares under the Share Repurchase Program.

13.Leases

The Company’s operating leases are primarily for office space, service facility centers and equipment under operating lease arrangements that expire at various dates over the next ten years. The Company’s leases do not contain any restrictive covenants. The Company’s office leases generally contain renewal options for periods ranging from one to five years. Because the Company is not reasonably certain to exercise these renewal options, the options are not considered in determining the lease term, and payments associated with the option years are excluded from lease payments. The Company’s office leases do not contain any material residual value guarantees. The Company’s equipment leases generally do not contain renewal options.

Payments due under the Company’s operating leases include fixed payments as well as variable payments. For the Company’s office leases, variable payments include amounts for the Company’s proportionate share of operating expenses, utilities, property taxes, insurance, common area maintenance and other facility-related expenses. For the Company’s equipment leases, variable payments may consist of sales taxes, property taxes and other fees.

The components of lease costs for the three and nine months ended September 30, 2021 and 2020 are as follows (in thousands):

						Three Months Ended September 30,												Nine Months Ended September 30,
						2021						2020						2021						2020
Operating lease cost						$	302					$	410					$	998					$	1,238
Variable lease cost						65						64						180						253
Total lease cost						$	367					$	474					$	1,178					$	1,491

Supplemental cash flow information and non-cash activity related to the Company’s leases are as follows (in thousands):

						Nine Months Ended September 30,
						2021						2020
Cash paid for amounts included in the measurement of lease liabilities and right of use assets:
Operating cash flow from operating leases						$	993					$	1,130
Right of use assets obtained in exchange for lease obligations:
Operating leases						$	288					$	260

Weighted average remaining lease terms and discount rates for the Company’s operating leases are as follows:

						As of September 30,
						2021						2020
						Years						Years
Weighted average remaining lease term:						6.3						7.1
						Rate						Rate
Weighted average discount rate:						7.7%						7.8%

17

---

Table of Contents

Future maturities of lease liabilities as of September 30, 2021 are as follows (in thousands):

						Operating Leases
2021						$	276
2022						1,183
2023						979
2024						949
2025						914
2026 and thereafter						2,253
Total undiscounted lease payments						6,554
Less: Imputed interest						(2,290)
Total lease liabilities						$	4,264

14.Business Segment Information

The Company’s reportable segments are organized based on service platforms, with the ITS segment reflecting higher margin rental revenues that generally include payments made by third-party and direct payers and the DME Services segment reflecting lower margin product sales and direct payer rental revenues. Resources are allocated and performance is assessed for these segments by the Company’s Chief Executive Officer, whom the Company has determined to be its chief operating decision-maker. The Company believes that reporting performance at the gross profit level is the best indicator of segment performance.

The financial information summarized below is presented by reportable segment for the three months ended September 30, 2021 and 2020:

2021
(in thousands)						ITS						DME Services						Corporate/ Eliminations						Total
Net revenues - external						$	16,581					$	9,985					$	—					$	26,566
Net revenues - internal						—						1,440						(1,440)						—
Total net revenues						16,581						11,425						(1,440)						26,566
Gross profit						10,574						4,684						—						15,258
Selling, general and administrative expenses																		15,609						15,609
Interest expense																		(270)						(270)
Other expense																		(44)						(44)
Benefit from income taxes																		217						217
Net loss																								$	(448)
Total assets						$	59,312					$	33,474					$	2,000					$	94,786
Purchases of medical equipment						$	4,058					$	644					$	—					$	4,702
Depreciation and amortization of intangible assets						$	2,785					$	955					$	—					$	3,740

18

---

Table of Contents

2020
(in thousands)						ITS						DME Services						Corporate/Eliminations						Total
Net revenues - external						$	15,638					$	9,487					$	—					$	25,125
Net revenues - internal						—						1,459						(1,459)						—
Total net revenues						15,638						10,946						(1,459)						25,125
Gross profit						10,095						5,027						—						15,122
Selling, general and administrative expenses																		11,869						11,869
Interest expense																		(283)						(283)
Other income																		8						8
Provision for income taxes																		(38)						(38)
Net income																								$	2,940
Total assets						$	51,547					$	26,761					$	2,000					$	80,308
Purchases of medical equipment						$	1,685					$	1,487					$	—					$	3,172
Depreciation and amortization of intangible assets						$	2,694					$	866					$	—					$	3,560

19

---

Table of Contents

The financial information summarized below is presented by reportable segment for the nine months ended September 30, 2021 and 2020:

2021
(in thousands)						ITS						DME Services						Corporate/ Eliminations						Total
Net revenues - external						$	48,826					$	27,037					$	—					$	75,863
Net revenues - internal						—						4,484						(4,484)						—
Total net revenues						48,826						31,521						(4,484)						75,863
Gross profit						31,028						13,856						—						44,884
Selling, general and administrative expenses																		43,666						43,666
Interest expense																		(909)						(909)
Other expense																		(150)						(150)
Benefit from income taxes																		874						874
Net income																								$	1,033
Total assets						$	59,312					$	33,474					$	2,000					$	94,786
Purchases of medical equipment						$	7,550					$	2,095					$	—					$	9,645
Depreciation and amortization of intangible assets						$	8,213					$	2,756					$	—					$	10,969

2020
(in thousands)						ITS						DME Services						Corporate/ Eliminations						Total
Net revenues - external						$	45,369					$	27,308					$	—					$	72,677
Net revenues - internal						—						3,955						(3,955)						—
Total net revenues						45,369						31,263						(3,955)						72,677
Gross profit						29,480						14,283						—						43,763
Selling, general and administrative expenses																		35,971						35,971
Interest expense																		(1,018)						(1,018)
Other expense																		(20)						(20)
Provision for income taxes																		(92)						(92)
Net income																								$	6,662
Total assets						$	51,547					$	26,761					$	2,000					$	80,308
Purchases of medical equipment						$	6,705					$	5,250					$	—					$	11,955
Depreciation and amortization of intangible assets						$	8,042					$	2,450					$	—					$	10,492

15.COVID-19

On March 11, 2020, the World Health Organization declared the outbreak of coronavirus (“COVID-19”) as a pandemic, which has spread globally and throughout the United States. During the period of the pandemic, we took a number of precautionary and preemptive steps to protect the safety and well-being of our employees while ensuring continuity of service to our clients, including, transitioning our employees to a remote work environment, suspending employee travel, canceling participation in industry events and in-person group meetings, promoting social distancing and enhanced cleaning and

20

---

Table of Contents

sanitization efforts across office locations, and implementing protocols to quarantine employees who may have been exposed to COVID-19, or show relevant symptoms. We also continued to undertake preparedness plans at our facilities to maintain continuity of operations, which provide for flexible work arrangements without any significant disruptions to our business or control processes. Our management team is continuing to actively monitor the situation and is in constant communication with our workforce, customers and vendors. While the COVID-19 pandemic has not had any material unfavorable effects in our financial results for the three or nine months ended September 30, 2021, the extent of any future impact will depend on future developments, which are highly uncertain, cannot be predicted and could have a material adverse impact on our financial position, operating results and cash flows.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The terms “InfuSystem”, the “Company”, “we”, “our” and “us” used herein refer to InfuSystem Holdings, Inc. and its subsidiaries.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this quarterly report on Form 10-Q are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “strategy,” “future,” “likely,” variations of such words, and other similar expressions, as they relate to the Company, are intended to identify forward-looking statements. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. In connection with the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, the Company is identifying certain factors that could cause actual results to differ, perhaps materially, from those indicated by these forward-looking statements. Those factors, risks and uncertainties include, but are not limited to, the effect of the coronavirus (“COVID-19”) pandemic or any resurgence thereof on our business, potential changes in healthcare payer mix and overall healthcare reimbursement, including the Centers for Medicare and Medicaid Services (“CMS”) competitive bidding and fee schedule reductions, sequestration, concentration of customers, increased focus on early detection of cancer, competitive treatments, dependency on Medicare Supplier Number, availability of chemotherapy drugs, global financial conditions, changes and enforcement of state and federal laws, natural forces, competition, dependency on suppliers, risks in acquisitions & joint ventures, U.S. Healthcare Reform, relationships with healthcare professionals and organizations, technological changes related to infusion therapy, the Company’s ability to implement information technology improvements and to respond to technological changes, the ability of the Company to successfully integrate acquired businesses, dependency on key personnel, dependency on banking relations and the ability to comply with our credit facility covenants, and other risks associated with our common stock, as well as any litigation in which the Company may be involved from time to time; and other risk factors as discussed in the Company’s annual report on Form 10-K for the year ended December 31, 2020 filed on March 22, 2021, this quarterly report on Form 10-Q and in other filings made by the Company from time to time with the Securities and Exchange Commission (“SEC”). Our annual report on Form 10-K is available on the SEC’s EDGAR website at www.sec.gov, and a copy may also be obtained by contacting the Company. All forward-looking statements made in this Form 10-Q speak only as of the date of this report. We do not intend, and do not undertake any obligation, to update any forward-looking statements to reflect future events or circumstances after the date of such statements, except as required by law.

Overview

We are a leading national health care service provider, facilitating outpatient care for Durable Medical Equipment manufacturers and health care providers. We provide our products and services to hospitals, oncology practices, ambulatory surgery centers, and other alternate site health care providers. Our headquarters is in Rochester Hills, Michigan, and we operate our business from a total of seven locations in the United States and Canada. We deliver local, field-based customer support as well as operate pump service and repair Centers of Excellence in Michigan, Kansas, California, Massachusetts, Texas and Ontario, Canada. InfuSystem, Inc., a wholly-owned subsidiary of the Company, is accredited by the Community Health Accreditation Partner while First Biomedical, Inc., a wholly-owned subsidiary of the Company, is ISO 9001 certified at our Kansas, Michigan, Massachusetts, Canada and Santa Fe Springs, California locations and also ISO 13485 certified at our Bakersfield, California location.

InfuSystem competes for and retains its business primarily on the basis of its long participation and strong reputation in the Durable Medical Equipment space, its long-standing relationships with Durable Medical Equipment manufacturers and its health care provider customers, and the high levels of service it provides. Current barriers to entry for potential competitors are created by our: (i) growing number of third-party payer networks under contract; (ii) economies of scale, which allow for predictable reimbursement and less costly purchase and management of the pumps, respectively; (iii) established, long-standing relationships as a provider of pumps to outpatient oncology practices in the U.S. and Canada; (iv) fleet of ambulatory and large

21

---

Table of Contents

volume infusion pumps for rent and for sale, which may allow us to be more responsive to the needs of physicians, outpatient oncology practices, hospitals, outpatient surgery centers, homecare practices, patient rehabilitation centers and patients than a new market entrant; (v) seven geographic locations in the U.S. and Canada that allow for same day or next day delivery of pumps; and (vi) pump repair and service capabilities at all of these facilities. We do not perform any research and development on pumps, but we have made, and continue to make investments in our information technology.

Integrated Therapy Services (“ITS”) Segment

Our ITS segment’s core purpose is to seek opportunities to leverage our unique know-how in clinic-to-home health care involving Durable Medical Equipment, our logistics and billing capabilities, our growing network of third-party payers under contract, and our clinical and biomedical capabilities. This leverage may take the form of new products and/or services, strategic alliances, joint ventures and/or acquisitions. The leading service within our ITS segment is to supply electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics and hospital outpatient oncology clinics to be utilized in the treatment of a variety of cancers including colorectal cancer and other disease states (“Oncology Business”). Colorectal cancer is the third most prevalent form of cancer in the United States, according to the American Cancer Society, and the standard of care for the treatment of colorectal cancer relies upon continuous chemotherapy infusions delivered via ambulatory infusion pumps. One of the primary goals for the ITS segment is to expand into treatment of other cancers. There are a number of approved treatment protocols for pancreatic, head and neck, esophageal and other cancers, as well as other disease states which present opportunities for growth. There are also a number of other drugs currently approved by the U.S. Food and Drug Administration, as well as agents in the pharmaceutical development pipeline, which we believe could potentially be used with continuous infusion protocols for the treatment of diseases other than colorectal cancer. Additional drugs or protocols currently in clinical trials may also obtain regulatory approval over the next several years. If these new drugs or protocols obtain regulatory approval for use with continuous infusion protocols, we expect the pharmaceutical companies to focus their sales and marketing efforts on promoting the new drugs and protocols to physicians.

Furthermore, our Oncology Business focuses mainly on the continuous infusion of chemotherapy. Continuous infusion of chemotherapy can be described as the gradual administration of a drug via a small, lightweight, portable infusion pump over a prolonged period of time. A cancer patient can receive his or her medicine anywhere from one to 30 days per month depending on the chemotherapy regimen that is most appropriate to that individual’s health status and disease state. This may be followed by periods of rest and then repeated cycles with treatment goals of progression-free disease survival. This drug administration method has replaced intravenous push or bolus administration in specific circumstances. The advantages of slow continuous low doses of certain drugs are well documented. Clinical studies support the use of continuous infusion chemotherapy for decreased toxicity without loss of anti-tumor efficacy. The 2015 National Comprehensive Cancer Network Guidelines recommend the use of continuous infusion for treatment of numerous cancer diagnoses. We believe that the growth of continuous infusion therapy is driven by three factors: evidence of improved clinical outcomes; lower toxicity and side effects; and a favorable reimbursement environment.

We believe that oncology practices have a heightened sensitivity to providing quality service and whether they are reimbursed for services they provide. Simultaneously, CMS and private insurers are increasingly focused on evidence-based medicine to inform their reimbursement decisions — that is, aligning reimbursement with clinical outcomes and adherence to standards of care. Continuous infusion therapy is a main component of the standard of care for certain cancer types because clinical evidence demonstrates superior outcomes. Payers’ recognition of this benefit is reflected in their relative reimbursement policies for clinical services related to the delivery of this care.

Additional areas of growth for our ITS segment are as follows:

•Pain Management - providing our ambulatory pumps, products, and services for pain management in the area of post-surgical continuous peripheral nerve block.

•Negative Pressure Wound Therapy (“NPWT”) - as announced in February 2020, NPWT includes providing the Durable Medical Equipment and related consumables, overseeing logistics, providing biomedical services, and managing third-party billing of the U.S. home healthcare market, which as a subset of the broader NPWT market, has an estimated addressable home healthcare market of $600 million per year.

•Lymphedema Therapy – as announced in June 2021, Lymphedema therapy includes providing patient care and customer service, pneumatic compression devices and associated garments through our partnership with Bio Compression Systems, Inc. to outpatients, initially targeting our existing acute care and oncology customers estimated to be 20% of the multi-billion-dollar Lymphedema market.

•Acquisitions - we believe there are opportunities to acquire smaller, regional health care service providers, in whole or part, that perform similar services to us but do not have the national market access, network of third-party payer contracts or operating economies of scale that we currently enjoy.

22

---

Table of Contents

•Information technology-based services - we also plan to continue to capitalize on key new information technology-based services such as EXPRESS, InfuSystem Mobile, InfuBus or InfuConnect, Pump Portal and BlockPain Dashboard®.

The payer environment within our ITS segment is in a constant state of change. We continue to extend our considerable breadth of payer networks under contract as patients move into different insurance coverages, including Medicaid and Insurance Marketplace products. In some cases, this may slightly reduce our aggregate billed revenues payment rate but result in an overall increase in collected revenues, due to a reduction in concessions. Consequently, we are increasingly focused on revenues net of concessions.

Durable Medical Equipment Services (“DME Services”) Segment

Our DME Services segment’s core service is to: (i) sell or rent new and pre-owned pole-mounted and ambulatory infusion pumps; (ii) sell treatment-related consumables; and (iii) provide biomedical recertification, maintenance and repair services for oncology practices as well as other alternate site settings including home care and home infusion providers, skilled nursing facilities, pain centers and others. We also provide these products and services to customers in the hospital market. We purchase new and pre-owned pole-mounted and ambulatory infusion pumps from a variety of sources on a non-exclusive basis. We repair, refurbish and provide biomedical certification for the devices as needed. The pumps are then available for sale, rental or to be used within our ambulatory infusion pump management service. Our recent acquisition of FilAMed, a privately-held biomedical services company, on January 31, 2021 will supplement the Company’s existing biomedical recertification, maintenance and repair services for acute care facilities and other alternate site settings including home care and home infusion providers, skilled nursing facilities, pain centers and others. Our recent acquisition of OB Healthcare Corporation (“OB Healthcare”), a privately-held biomedical services company, on April 18, 2021 further develops and expands InfuSystem’s DME Services segment and complements the Company’s purchase of FilAMed.

COVID-19 Update

On March 11, 2020, the World Health Organization declared the outbreak of COVID-19 as a pandemic, which has spread globally and throughout the United States. During the period of the pandemic, we took a number of precautionary and preemptive steps to protect the safety and well-being of our employees while ensuring continuity of service to our clients, including, transitioning our employees to a remote work environment, suspending employee travel, canceling participation in industry events and in-person group meetings, promoting social distancing and enhanced cleaning and sanitization efforts across office locations, and implementing protocols to quarantine employees who may have been exposed to COVID-19, or show relevant symptoms. We also continued to undertake preparedness plans at our facilities to maintain continuity of operations, which provide for flexible work arrangements without any significant disruptions to our business or control processes. Our management team is continuing to actively monitor the situation and is in constant communication with our workforce, customers and vendors. While the COVID-19 pandemic has not had any material unfavorable effects in our financial results for the three and nine months ended September 30, 2021, the extent of any future impact will depend on future developments, which are highly uncertain, cannot be predicted and could have a material adverse impact on our financial position, operating results and cash flows.

23

---

Table of Contents

InfuSystem Holdings, Inc. Results of Operations for the Three Months Ended September 30, 2021 Compared to the Three Months Ended September 30, 2020

The following represents the Company’s results of operations for the three months ended September 30, 2021 and 2020:

									Three Months Ended September 30,
(in thousands, except share and per share data)									2021						2020						Better (Worse)
Net revenues:
ITS									$	16,581					$	15,638					$	943
DME Services (inclusive of inter-segment revenues)									11,425						10,946						479
Less: elimination of inter-segment revenues									(1,440)						(1,459)						19
Total									26,566						25,125						1,441
Gross profit (inclusive of certain inter-segment allocations) (a):
ITS									10,574						10,095						479
DME Services									4,684						5,027						(343)
Total									15,258						15,122						136
Selling, general and administrative expenses
Provision for doubtful accounts									10						11						1
Amortization of intangibles									1,125						1,075						(50)
Selling and marketing									2,908						2,196						(712)
General and administrative									11,566						8,587						(2,979)
Total selling, general and administrative expenses									15,609						11,869						(3,740)
Operating (loss) income									(351)						3,253						(3,604)
Other expense									(314)						(275)						(39)
(Loss) income before income taxes									(665)						2,978						(3,643)
Benefit from (provision for) income taxes									217						(38)						255
Net (loss) income									$	(448)					$	2,940					$	(3,388)
Net (loss) income per share
Basic									$	(0.02)					$	0.15					$	(0.17)
Diluted									$	(0.02)					$	0.14					$	(0.16)
Weighted average shares outstanding:
Basic									20,577,886						20,179,056						398,830
Diluted									20,577,886						21,663,414						(1,085,528)
(a) Inter-segment allocations are for cleaning and repair services performed on medical equipment.

Net Revenues

Net revenues for the quarter ended September 30, 2021 (“third quarter of 2021”) were $26.6 million, an increase of $1.4 million, or 5.7%, compared to $25.1 million for the quarter ended September 30, 2020 (“third quarter of 2020”). The increase was due to higher service and repair revenues and higher net revenue for all three ITS Segment therapies. These increases were partially offset by decreases in DME Services rental revenues and sales of medical equipment.

24

---

Table of Contents

ITS

ITS net revenue of $16.6 million increased $0.9 million, or 6.0%, during the third quarter of 2021 as compared to the prior year period. This increase was primarily attributable to improved third party payer collections on billings for Oncology and additional treatment volume in Pain Management and NPWT. Pain Management net revenue for the third quarter of 2021 increased as compared to the prior year third quarter due to additional sites of care added over the last year. NPWT was launched during the first quarter of 2020 but did not start to have measurable quarterly revenues until the second half of 2020. On a combined basis, Pain Management and NPWT net revenues increased by $0.3 million during the third quarter of 2021 as compared to the same period in 2020, which represented an increase of 30.2%.

DME Services

DME Services net revenue of $10.0 million increased $0.5 million, or 5.2%, during the third quarter of 2021 as compared to the prior year period. This increase was mainly due to net revenues from the acquisitions of FilAMed and OB Healthcare which were acquired during the first quarter of 2021 and second quarter of 2021, respectively. These increases were partially offset by lower rental revenues and equipment sales due to a moderation in market demand for infusion pumps which was elevated during the third quarter of 2020 because of the COVID-19 pandemic.

Gross Profit (inclusive of certain inter-segment allocations)

Gross profit for the third quarter of 2021 of $15.3 million increased $0.1 million, or 0.9%, from $15.1 million for the third quarter of 2020. The increase was driven by the increase in net revenues offset partially by a lower gross profit as a percentage of net revenue (“gross margin”). Gross margin was 57.4% during the third quarter of 2021 as compared to 60.2% during the prior year, a decrease of 2.8%. Gross margin decreased in both the DME Services and ITS segments.

ITS

ITS gross profit was $10.6 million during the third quarter of 2021, representing an increase of $0.5 million compared to the prior year. The improvement reflected an increase in net revenues offset partially by a lower gross margin, which decreased from the prior year by 0.8% to 63.8%. The lower gross margin was the result of higher pump maintenance expenses and pump disposal costs as compared to the prior year. Pump maintenance expenses, which include preventative maintenance, cleaning and repair services mainly performed by the DME Services segment, were unusually low during the third quarter of 2020 due to COVID-19 when we deployed a significant number of newly purchased pumps. Pump disposal expenses include retirements of damaged pumps and reserves for missing pumps.

DME Services

DME Services gross profit during the third quarter of 2021 was $4.7 million, representing a decrease of $0.3 million, or 6.8%, compared to the prior year. This decrease was due to a lower gross margin offset partially by an increase in net revenues. The DME gross margin was 46.9% during the current quarter, which was 6.1% lower than the prior year. This decrease was the result of gross margin mix associated with lower rental revenues, an increase in labor costs related to an increase in biomedical technicians and an increase in freight expense. The increase in biomedical technician labor resulted from an increase in team members who were hired in order to increase the capacity in biomedical services in anticipation of increased biomedical services demand. These newly hired team members mainly spent their time training during the period but will be deployed to support higher demand and related revenue volumes in future quarters. The increase in freight expense was partially due to increased outbound shipping activities at the end of the third quarter of 2021 to deploy rental devices which will begin generating rental revenues during the 2021 fourth quarter.

Selling and Marketing Expenses

Selling and marketing expenses for the third quarter of 2021 were $2.9 million, representing an increase of $0.7 million, or 32.4%, as compared to the third quarter of 2020. Selling and marketing expenses as a percentage of net revenues increased to 10.9% compared to the prior year period at 8.7%. This increase reflected $0.5 million in higher expenses for NPWT and Pain Management dedicated sales personnel hired during the 2021 second quarter and higher customer travel expenses. The additional sales team members represent a strategic investment to accelerate revenue growth for these therapies and the expense included in selling and marketing is a portion of an overall expense increase of $0.8 million, for the third quarter of 2021 associated with this initiative, the remainder of which is included in general and administrative expense. These increases were partially offset by a reduction in expenses associated with a sales team reorganization completed in late 2020. The higher travel expenses occurred as travel restrictions related to COVID-19 were lifted earlier during the year. During the third quarter of 2020, when the COVID-19 related travel restrictions were at their peak, our sales team generally did not travel. The selling and

25

---

Table of Contents

marketing expenses during these periods consisted of sales personnel salaries, commissions and associated fringe benefit and payroll-related items, marketing, travel and entertainment and other miscellaneous expenses.

General and Administrative Expenses

General and administrative (“G&A”) expenses for the third quarter of 2021 were $11.6 million, an increase of 34.7% from $8.6 million for the third quarter of 2020. G&A expenses during these periods consisted primarily of accounting, administrative, third-party payer billing and contract services, customer service, nurses on staff, new product services, service center personnel salaries, fringe benefits and other payroll-related items, professional fees, legal fees, stock-based compensation, insurance and other miscellaneous items. The increase of $3.0 million was largely due to an increase in stock-based compensation expense of $1.3 million, $0.3 million in additional expenses related to the investments in NPWT and Pain Management, $0.2 million of additional G&A expenses for FilAMed and OB Healthcare, higher travel expenses and other increases including higher personnel and general business expenses. G&A expenses as a percentage of net revenues for the third quarter of 2021, increased to 43.5% compared to 34.2% for the prior year mainly reflecting the year-over-year increases partially offset by improved net revenue leverage over fixed costs.

Other Expenses

During the third quarter of 2021, other expense included interest expense of $0.3 million which was slightly lower than interest expense for the third quarter of 2020. This decrease resulted from lower average outstanding debt balances offset by higher weighted average interest rates and additional commitment fees on a higher unused revolving line availability during the third quarter of 2021 as compared to 2020.

Benefit From (Provision For) Income Taxes

During the third quarter of 2021, the Company recorded a benefit from income taxes totaling $0.2 million representing an effective tax rate of 32.6% on a pre-tax loss of $0.7 million. This effective tax rate differed from the U.S. statutory rate mainly due to the effects of local, state and foreign jurisdiction income taxes.

As of December 31, 2020, the Company had generated significant pre-tax income on a three-year cumulative basis prompting management to assess available positive and negative evidence regarding the recovery of our net deferred tax assets. Due to this assessment, it was determined that it is more likely than not that the Company will recognize the benefits of its federal and state net deferred tax assets and, as a result, a previously recorded valuation allowance was released. Prior to this date, our tax provisions and benefits were significantly offset by adjustments to the valuation allowance.

During the third quarter of 2020, we recorded a provision for income taxes of less than $0.1 million, representing an effective tax rate of 1.3% on pre-tax earnings totaling $3.0 million. The effective tax rates differed from the U.S. statutory rates during this period due mainly to the availability of net operating losses almost fully offsetting the then current tax provision in most jurisdictions we operated in and a decrease in the valuation reserve recorded on our net deferred tax assets, which fully offset our deferred tax provision during that period.

26

---

Table of Contents

InfuSystem Holdings, Inc. Results of Operations for the Nine Months Ended September 30, 2021 Compared to the Nine Months Ended September 30, 2020

The following represents the Company’s results of operations for the nine months ended September 30, 2021 and 2020:

									Nine Months Ended September 30,
(in thousands, except share and per share data)									2021						2020						Better/ (Worse)
Net revenues:
ITS									$	48,826					$	45,369					$	3,457
DME Services (inclusive of inter-segment revenues)									31,521						31,263						258
Less: elimination of inter-segment revenues									(4,484)						(3,955)						(529)
Total									75,863						72,677						3,186
Gross profit (inclusive of certain inter-segment allocations) (a):
ITS									31,028						29,480						1,548
DME Services									13,856						14,283						(427)
Total									44,884						43,763						1,121
Selling, general and administrative expenses
Provision for doubtful accounts									(99)						534						633
Amortization of intangibles									3,264						3,225						(39)
Selling and marketing									7,964						7,263						(701)
General and administrative									32,537						24,949						(7,588)
Total selling, general and administrative expenses									43,666						35,971						(7,695)
Operating income									1,218						7,792						(6,574)
Other expense									(1,059)						(1,038)						(21)
Income before income taxes									159						6,754						(6,595)
Benefit from (provision for) income taxes									874						(92)						966
Net income									$	1,033					$	6,662					$	(5,629)
Net income per share
Basic									$	0.05					$	0.33					$	(0.28)
Diluted									$	0.05					$	0.31					$	(0.26)
Weighted average shares outstanding:
Basic									20,468,842						20,060,416						408,426
Diluted									21,995,216						21,637,481						357,735
(a) Inter-segment allocations are for cleaning and repair services performed on medical equipment.

27

---

Table of Contents

Net Revenues

Net revenues for the nine-month period ended September 30, 2021 (“nine-month period of 2021”) were $75.9 million, an increase of $3.2 million, or 4.4%, compared to $72.7 million for the nine-month period ended September 30, 2020 (“nine-month period of 2020”). The increase was due to higher service volumes for all three ITS Segment therapies, improved collections on billings to third party payers and higher service and repair revenues. These increases were offset partially by lower medical equipment sales in the DME Services Segment.

ITS

ITS net revenue of $48.8 million increased $3.5 million, or 7.6%, during the nine-month period of 2021 as compared to the prior year period. This increase was primarily attributable to growth in the Company’s customer base due to favorable changes in the competitive environment for oncology services, higher service volumes for Pain Management and new revenues from NPWT. Adding to these increases was improved third-party payer collections on billings and other market-related organic growth. Pain Management net revenue for the nine-month period of 2021 increased as compared to the nine-month period of 2020 due to additional sites of care added over the last year and a recovery in the elective surgeries market which was negatively impacted by COVID-19 during the second quarter of 2020. The new NPWT business was launched during the first quarter of 2020 but did not start to have measurable quarterly revenues until the second half of 2020. On a combined basis, Pain Management and NPWT net revenues increased by $1.5 million during the nine-month period of 2021 as compared to the same period in 2020, which represented an increase of 72.6%.

DME Services

DME Services net revenue of $27.0 million, decreased $0.3 million, or 1.0%, during the nine-month period of 2021 as compared to the prior year period. This decrease was mainly due to a moderation in market demand for infusion pumps which was elevated during the second quarter of 2020 because of the COVID-19 pandemic partially offset by the expansion of our market share with national home infusion service providers, the addition of new devices to our product offerings stemming from new partnerships with certain medical device manufacturers and revenues from FilAMed and OB Healthcare which were acquired during the first quarter of 2021 and second quarter of 2021, respectively.

Gross Profit (inclusive of certain inter-segment allocations)

Gross profit for the nine-month period of 2021 of $44.9 million increased $1.1 million, or 2.6%, from $43.8 million for the nine-month period of 2020. This increase was due to the increase in net revenues offset by a lower gross margin. Gross margin decreased slightly to 59.2% during the nine-month period of 2021 as compared to 60.2% during the prior year. This decrease was due to a decrease in the gross margin for both the DME Services and ITS segments.

ITS

ITS gross profit was $31.0 million during the nine-month period of 2021, representing an increase of $1.5 million, or 5.3%, compared to the prior year. The improvement reflected an increase in net revenues offset partially by a lower gross margin, which decreased from the prior year by 1.5% to 63.5%. The lower gross margin was the result of a non-cash reserve adjustment of $0.4 million recorded for missing medical equipment, higher pump maintenance expenses offset partially by improved collections on billings during the current period. The reserve adjustment for missing equipment was significantly higher than normal during the first quarter of 2021. Pump maintenance expenses, which include preventative maintenance, cleaning and repair services mainly performed by the DME Services segment, were unusually low during the prior year due to COVID-19 when the Company deployed a significant number of newly purchased pumps.

DME Services

DME Services gross profit during the nine-month period of 2021 was $13.9 million, representing a decrease of $0.4 million, or 3.0%, over the prior year. This decrease was due to the decrease in net revenues and gross margin. The DME gross margin was 51.2% during the current period, which was 1.1% lower than the prior year. This decrease was the result of unfavorable gross margin mix associated with lower rental revenue, an increase in labor costs related to an increase in biomedical technicians who were being trained during the third quarter of 2021 and an increase in freight expense partially associated with shipments of rental units at the end of the third quarter of 2021.

28

---

Table of Contents

Provision for Doubtful Accounts

Provision for doubtful accounts for the nine-month period of 2021 included a favorable accrual reversal resulting in the net amount to be a benefit of $0.1 million during the period as compared to a $0.5 million expense recorded for the nine-month period of 2020. The accrual reversal was the result of improved collections on late accounts.

Selling and Marketing Expenses

Selling and marketing expenses for the nine-month period of 2021 were $8.0 million, representing an increase of $0.7 million or 9.7% as compared to selling and marketing expenses for the nine-month period of 2020. Selling and marketing expenses as a percentage of net revenues increased to 10.5% compared to the prior year period at 10.0%. This increase reflected $0.8 million in higher expenses for NPWT and Pain Management dedicated sales personnel hired during the 2021 second quarter and higher customer travel expenses. These increases were partially offset by a decrease that reflected a shift in the proportion of net revenue favoring the DME Services segment, which has a lower commission to sales ratio than the ITS segment, lower expenses associated with a management reorganization completed during the fourth quarter of 2020 and improved net revenue leverage of fixed selling and marketing expenses. Selling and marketing expenses during these periods consisted of sales personnel salaries, commissions and associated fringe benefit and payroll-related items, marketing, travel and entertainment and other miscellaneous expenses.

General and Administrative Expenses

G&A expenses for the nine-month period of 2021 were $32.5 million, an increase of $7.6 million or 30.4% from the nine-month period of 2020. G&A expenses during these periods consisted primarily of accounting, administrative, third-party payer billing and contract services, customer service, nurses on staff, new product services, service center personnel salaries, fringe benefits and other payroll-related items, professional fees, legal fees, stock-based compensation, insurance and other miscellaneous items. The increase was largely due to an increase in stock-based compensation expense of $3.7 million, lower than normal expenses during the second quarter of 2020 due to COVID-19 related deferrals of various internal projects of nearly $1.0 million, $0.5 in additional expenses related to the investments in NPWT and Pain Management and the additional G&A expenses and acquisition expenses for FilAMed and OB Healthcare totaling $0.4 million. The additional increase of $2.0 million included higher personnel and general business expenses. G&A expenses as a percentage of net revenues for the nine-month period of 2021, increased to 42.9% compared to 34.3% for the prior year mainly reflecting the year-over-year increases partially offset by improved net revenue leverage over fixed costs.

Other Income and Expenses

During the nine-month period of 2021, other income and expense included interest expense of $0.9 million which was $0.1 million lower than interest expense for the nine-month period of 2020. This decrease resulted from lower average outstanding debt balances offset by higher weighted average interest rates and additional commitment fees on a higher unused revolving line availability during the nine-month period of 2021 as compared to 2020.

Benefit From (Provision For) Income Taxes

During the nine-month period of 2021, the Company recorded a benefit from income taxes totaling $0.9 million. This amount included a benefit due to an excess tax benefit associated with a higher amount of equity compensation expense deductible for tax purposes as compared to amounts historically recognized for book purposes on exercises of stock options and vesting of restricted stock during the first half of 2021. This benefit was partially offset by an estimated tax provision totaling $0.1 million representing an effective tax rate of 36.3% on pre-tax income totaling $0.2 million. This effective tax rate differed from the U.S. statutory rate mainly due to the effects of local, state and foreign jurisdiction income taxes.

During the nine-month period of 2020, we recorded a provision for income taxes of less than $0.1 million, representing an effective tax rate of 1.4% on pre-tax earnings of $6.8 million. The effective tax rate during this period differed from the U.S. statutory rates during this period due mainly to the availability of net operating losses almost fully offsetting the then current tax provision in most jurisdictions we operated in and a decrease in the valuation reserve recorded on our net deferred tax assets, which fully offset our deferred tax provision during that period.

29

---

Table of Contents

Liquidity and Capital Resources

Overview:

We finance our operations and capital expenditures with internally-generated cash from operations and borrowings under our credit facilities. On February 5, 2021, we and certain of our subsidiaries, as borrowers, entered into a Credit Agreement (the “2021 Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent, sole bookrunner and sole lead arranger, and the lenders party thereto, which replaced our then existing credit facility, dated March 23, 2015 (the “2015 Credit Agreement”). See Note 8 (Debt) in the notes to the accompanying unaudited condensed consolidated financial statements for additional information regarding the 2021 Credit Agreement and 2015 Credit Agreement.

The following table summarizes our available liquidity (in millions):

Liquidity
			September 30, 2021						December 31, 2020
Cash and cash equivalents			$	0.2					9.6
Revolving line of credit			43.4						10.8
Available liquidity			$	43.6					20.4

Our liquidity and borrowing plans are established to align with our financial and strategic planning processes and ensure we have the necessary funding to meet our operating commitments, which primarily include the purchase of pumps, inventory, payroll and general expenses. We also take into consideration our overall capital allocation strategy, which includes investment for future organic growth, potential acquisitions and share repurchases. We believe we have adequate sources of liquidity and funding available for at least the next year. However, any projections of future earnings and cash flows are subject to substantial uncertainty, including factors such as the successful execution of our business plan and general economic conditions. We may need to access debt and equity markets in the future if unforeseen costs or opportunities arise, to meet working capital requirements, fund acquisitions or investments or repay indebtedness under the 2021 Credit Agreement. If we need to obtain new debt or equity financing in the future, the terms and availability of such financing may be impacted by economic and financial market conditions as well as our financial condition and results of operations at the time we seek additional financing.

Long-Term Debt Activities:

The Company executed and closed the 2021 Credit Agreement during the first quarter of 2021, and in connection with entering into that agreement, terminated the 2015 Credit Agreement. For the following table, the figures related to the September 30, 2021 revolving credit facility (the “Revolving Facility”) balances relate to the 2021 Credit Agreement, while the December 31, 2020 revolving credit facility balances relate to the now-terminated 2015 Credit Agreement. The following table illustrates the net availability under the revolving credit facilities as of the applicable balance sheet date (in thousands):

						September 30, 2021						December 31, 2020
Revolving Facility:
Gross availability						$	75,000					$	11,750
Outstanding draws						(30,804)						—
Letters of credit						(800)						(800)
Landlord reserves						—						(162)
Availability on Revolving Facility						$	43,396					$	10,788

As of September 30, 2021, amounts outstanding under the Revolving Facility provided under the 2021 Credit Agreement bear interest at a variable rate equal to, at the Company’s election, a LIBO Rate for Eurodollar loans or an Alternative Base Rate for ABR loans, as defined by the 2021 Credit Agreement, plus a spread that will vary depending upon the Company’s leverage ratio. The spread ranges from 2.00% to 3.00% for Eurodollar Loans and 1.00% to 2.00% for base rate loans. The weighted-average Eurodollar loan rate at September 30, 2021 was 2.09% (LIBO of 0.09% plus 2.00%). The actual ABR loan rate at September 30, 2021 was 4.25% (lender’s prime rate of 3.25% plus 1.00%). As of September 30, 2021, the Company was in compliance with all debt-related covenants under the 2021 Credit Agreement.

Share Repurchase Program

30

---

Table of Contents

On June 30, 2021, our Board of Directors approved a stock repurchase program (the “Share Repurchase Program”) authorizing the Company to repurchase up to $20.0 million of the Company’s outstanding common stock through June 30, 2024. The repurchase program will be subject to market conditions, the periodic capital needs of the Company’s operating activities, and the continued satisfaction of all covenants under the Company’s existing 2021 Credit Agreement. Repurchases under the program may take place in the open market or in privately negotiated transactions and may be made under a Rule 10b5-1 plan. The repurchase program does not obligate the Company to repurchase shares and may be suspended, terminated, or modified at any time.

As of September 30, 2021, the Company had not repurchased any shares under the Share Repurchase Program.

Cash Flows:

The following table summarizes our cash flows (in millions):

						Nine Months Ended September 30,
In millions						2021						2020						2021 vs. 2020
Net cash provided by operating activities						$	14.6					$	12.7					$	1.9
Net cash used in investing activities						$	(15.7)					$	(9.0)					$	(6.7)
Net cash used in financing activities						$	(8.4)					$	(4.4)					$	(4.0)

Operating Cash Flow. Net cash provided by operating activities for the nine-month period of 2021 was $14.6 million compared to $12.7 million for the nine-month period of 2020. This $1.9 million, or 15.3%, increase was primarily attributable to the positive cash flow effect of a lower amount of cash invested in working capital balances during 2021 as compared to 2020 offset partially by a decrease in net income adjusted for non-cash items of $15.4 million during the nine-month period of 2021 as compared to $16.1 million during the nine-month period of 2020, a decrease of $0.8 million, or 4.7%. During the nine month period ended 2021, cash invested in working capital balances totaled $0.8 million, which included a $0.2 million decrease in accounts receivable, a $0.6 million increase in inventory and a $0.5 million decrease in accounts payable and accrued liabilities. This amount represented a $2.7 million decrease as compared to the same period in 2020 when investments in working capital balances totaled $3.5 million and included a $1.5 million increase in accounts receivable, a $1.1 million increase in inventories and a $0.9 million decrease in accounts payable and accrued liabilities.

The $0.2 million decrease in accounts receivable during the nine-month period of 2021 as compared to the $1.5 million increase during the prior year was mainly due to a lower growth in net revenues and improved customer collections during the 2021 period as compared to the prior year period. Inventory increased by $0.6 million during the nine-month period of 2021, which was lower than the prior year period amount of $1.1 million when the Company purchased a safety stock of disposable medical supplies in anticipation of potential supply disruptions as the COVID-19 pandemic began to unfold. Accounts payable and other liabilities, net of capital items, decreased by $0.5 million during the nine-month period of 2021, which was lower than the prior year decrease of $0.9 million as a result of the increase in purchases of disposable medical supplies related to the increase in inventory and the higher amount of revenue growth during 2020.

Investing Cash Flow. Net cash used in investing activities was $15.7 million for the nine-month period of 2021 compared to $9.0 million for the nine-month period of 2020, an increase of $6.7 million. The increase was due to the acquisitions of FilAMed and OB Healthcare totaling $7.7 million during the nine-month period of 2021. There were no acquisitions during 2020. This amount was partially offset by a decrease in cash used to purchase medical equipment and other property and equipment of $2.3 million and $0.3 million, respectively. Purchases of medical equipment were higher during 2020 since, during that period, the Company was adding additional equipment to prepare for the onset of COVID-19 which, at the time, was causing an increased market demand for the Company’s services while also potentially threatening the supply chain for new medical equipment.

Financing Cash Flow. Net cash used in financing activities for the nine-month period of 2021 was $8.4 million compared to $4.4 million for the nine-month period of 2020. The use of cash during 2021 was mainly related to the refinancing of our bank debt on February 5, 2021. Prior to that date, we operated under the 2015 Credit Agreement which included three term notes and a revolving line of credit. At the beginning of 2021, we had $9.6 million in cash on hand and no outstanding borrowings under the revolving line of credit. The 2015 Credit Agreement was completely repaid and replaced by the 2021 Credit Agreement, which has a new $75 million revolving line of credit and no term notes. This structure allowed the Company to use a portion of its available cash, totaling $7.9 million, to reduce its overall outstanding debt on the closing date of the financing. Other amounts of cash used in financing activities during the nine-month period of 2021 included net revolving line of credit repayments under the 2021 Credit Agreement made from our operating cash flows after the date of the February 5, 2021 refinancing totaling $6.8 million and $0.5 million in principal payments on our other financing. These amounts were

31

---

Table of Contents

partially offset by revolving line of credit borrowings totaling $7.7 million used to acquire FilAMed and OB Healthcare. Net cash used in financing activities for the nine-month period of 2020 included a $3.1 million net reduction in outstanding borrowings under the 2015 Credit Agreement which included amortization installments on term notes totaling $5.8 million partially offset by $2.7 million in borrowings under an equipment line of credit.

Critical Accounting Policies and Estimates

The unaudited condensed consolidated financial statements are prepared in conformity with GAAP, which require the use of estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses in the periods presented. We believe that the accounting estimates employed are appropriate and resulting balances are reasonable; however, due to inherent uncertainties in making estimates, actual results could differ from the original estimates, requiring adjustments to these balances in future periods. The critical accounting estimates that affect the unaudited condensed consolidated financial statements and the judgments and assumptions used are consistent with those described in the notes to the audited consolidated financial statements in our annual report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 22, 2021. There have been no material changes to our critical accounting policies described in the notes to the audited consolidated financial statements in our annual report on Form 10-K for the year ended December 31, 2020.

As of the date of the unaudited condensed consolidated financial statements presented in this Form 10-Q, there have been no material negative financial impacts on our operations resulting from the COVID-19 pandemic. However, the future effects of this pandemic or any resurgence thereof on economic and market conditions is uncertain and increases the subjectivity that will be involved in evaluating our estimates and assumptions underlying our critical accounting policies. Any events and changes in circumstances arising after September 30, 2021, including those resulting from the impacts of the COVID-19 pandemic, will be reflected in management’s estimates for future periods.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures and Changes in Internal Control over Financial Reporting

We maintain a set of disclosure controls and procedures designed to ensure that material information required to be disclosed in our filings under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that material information is accumulated and communicated to our management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), as appropriate, to allow timely decisions regarding required disclosures. Our CEO and CFO have evaluated these disclosure controls and procedures as of the end of the period covered by this quarterly report on Form 10-Q and have determined that such disclosure controls and procedures were effective.

There has been no change in our internal control over financial reporting during our most recent calendar quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

Item 1. Legal Proceedings

From time to time in the ordinary course of our business, we may be involved in legal and regulatory proceedings, the outcomes of which may not be determinable. The results of litigation and regulatory proceedings are inherently unpredictable. Any claims against us, whether meritorious or not, could be time consuming, result in costly litigation, require significant amounts of management time and result in diversion of significant resources. We are not able to estimate an aggregate amount or range of reasonably possible losses for those legal matters for which losses are not probable and estimable, primarily for the following reasons: (i) many of the relevant legal proceedings are in preliminary stages and until such proceedings develop further, there is often uncertainty regarding the relevant facts and circumstances at issue and potential liability; and (ii) many of these proceedings involve matters of which the outcomes are inherently difficult to predict. We have insurance policies covering potential losses where such coverage is cost effective.

32

---

Table of Contents

We are not at this time involved in any proceedings that we believe could have a material effect on our business, financial condition, results of operations or cash flows.

Item 1A. Risk Factors

For information regarding factors that could affect our results of operations, financial condition and liquidity, refer to the section entitled “Risk Factors” in Part I, Item 1A in our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 22, 2021.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

33

---

Table of Contents

Item 6. Exhibits

Exhibits
3.1			Amended and Restated Certificate of Incorporation, as amended (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on May 12, 2014).
3.2			Amended and Restated By-Laws (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on July 9, 2018).
31.1*			Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*			Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1***			Certification of Chief Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2***			Certification of Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*			Inline XBRL Instance Document – the instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document
101.SCH*			Inline XBRL Taxonomy Extension Schema Document
101.CAL*			Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*			Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*			Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*			Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*			Cover Page Interactive Data File – formatted in Inline XBRL and contained in Exhibit 101
* ***			Filed herewith Furnished herewith

34

---

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			INFUSYSTEM HOLDINGS, INC.
Date: November 15, 2021						/s/ Richard DiIorio
						Richard DiIorio
						Chief Executive Officer and Director (Principal Executive Officer)

Date: November 15, 2021						/s/ Barry Steele
						Barry Steele Chief Financial Officer (Principal Accounting and Financial Officer)

35